Drugs / ATLCAR.CD30 cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02663297 | Jun 2016 → Jan 2021 overdue | classic Hodgkin lymphoma, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome +1 | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02690545 | Aug 2016 → Dec 2025 overdue | immunoproliferative disorder, lymphatic system disorder, non-Hodgkin lymphoma | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATLCAR.CD30 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02663297 ↗ |
| Action | Deplete | “These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor” NCT02663297 ↗ |
| Modality | Cell therapy | “autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration” NCT02690545 ↗ |
| Route | Intravenous | “ATLCAR.CD30 cells will be given by a licensed provider (oncology nurse or physician) via intravenous injection” NCT02690545 ↗ |